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• Estradiol substitution significantly reduced the cortical infarct area and improved 
neurological scoring in the tMCAO model. 
• tMCAO increased CD45+ and CD45+CD11b+CD11c+ cell percentages. 
• Estradiol prevented the increase in CD45+ and CD45+CD11b+CD11c+ cell numbers. 
• Estradiol selectively regulated neuroinflammatory responses mediated by microglia- or 







Ischemic stroke is the leading cause of human disability and mortality in the world. 
Neuroinflammation is the main pathological event following ischemia which contributes to 
secondary brain tissue damage which is driven by infiltration of circulating immune cells such as 
macrophages. Because of neuroprotective properties against ischemic brain damage, estrogens 
have the potential to become of therapeutic interest. However, the exact mechanisms of 
neuroprotection and signaling pathways is not completely understood. In the current study, 12-
week-old male Wistar rats underwent an experimental ischemia by occluding the middle cerebral 
artery transiently (tMCAO) for 1 h. Male rats subjected to tMCAO were randomly assigned to 
receive 17-estradiol or vehicle treatment. The animals were sacrificed 72 h post tMCAO, 
transcardially perfused and the brains were proceeded either for TTC staining and gene analysis 
or for flow cytometry (CD45, CD11b, CD11c, CD40). We found that 17-estradiol substitution 
significantly reduced the cortical infarct which was paralleled by an improved Garcia test scoring. 
Flow cytometry revealed that CD45+ cells as well as CD45+CD11b+CD11c+ cells were massively 
increased in tMCAO animals and numbers were nearly restored to sham levels after 17-estradiol 
treatment. Gene expression analysis showed a reperfusion time-dependent upregulation of the 
markers CD45, CD11b and the activation marker CD40. The reduction in gene expression after 
72 hours of reperfusion and simultaneous 17-estradiol substitution did not reach statistical 
significance. These data indicate that 17-estradiol alleviated the cerebral ischemia-reperfusion 
injury and selectively suppressed the activation of the neuroinflammatory cascade via reduction 




Estrogens are the primary female sex hormones that are responsible for female reproduction and 
act through binding to nuclear estrogen receptors (nER) which modulate the expression of many 
genes such as lipocalin-2, angiotensin or progesterone receptor [1, 2]. Besides, estrogens can 
bind and activate membrane-bound ERs (mER) which are accountable for many so-called non-
genomic estrogen effects such as sexual behavior, pain perception or the prevention of vascular 
injury [3-5]. In addition to reproductive functions, estrogens also regulate neuronal differentiation 
and brain function [6]. There is growing evidence that estrogens can modulate a number of 
peripheral immune cell functions as well as neuro-immune responses in the central nervous 
system (CNS) [6, 7]. The pathophysiology and outcome after neurological injuries often reveals a 




to the disease course and severity in some way or another [8]. A number of experimental studies 
in the past decade have now proven that estrogens act anti-inflammatory and neuroprotective in 
many models of brain injury, including stroke and Alzheimer’s disease [9, 10]. One of the first 
studies showing that estrogens have a protective effect on ischemic stroke outcome was 
conducted by Simpkins and colleagues in 1997 [11]. In this study, various 17-estradiol (in the 
following 17-estradiol is stated as “estradiol”) concentrations were administered to female 
ovariectomized rats after MCA occlusion which led to a decrease of mortality and a reduced 
ischemic area. In the sequel, many studies have proven the neuroprotective effects of estrogens 
mainly in disease-related animal models [12-14]. Using a transient ischemic stroke rat model 
(transient middle cerebral artery occlusion, tMCAO), a spinal cord injury rat model, an amyotrophic 
lateral sclerosis mouse model (SOD1G93A) and a multiple sclerosis mouse model, we have 
demonstrated in a series of studies that estradiol exerts a neuroprotective role, thereby reducing 
tissue damage and neuronal death [15-17]. All the projects have in common that estradiol rapidly 
within hours dampens neuroinflammation and microgliosis. In vitro studies further revealed that 
estradiol modulates the activation of microglia and promotes the differentiation towards a more 
phagocytic and rather protective M2 phenotype [18]. 
Ischemic stroke is the fourth leading cause of death and the leading cause of neurological disability 
worldwide. Generally, ischemic conditions in the brain are generated by a sudden occlusion of a 
cerebral artery by a local thrombus or embolus [19]. Ischemia leads to an insufficient blood and 
oxygen supply resulting in neuronal death along with later occurring reperfusion injuries [20]. The 
mechanisms of neuronal cell death after cerebral ischemia have not been fully understood but 
both necrotic and apoptotic cell death as well as pyroptosis are present in the infarct area. In 
ischemic stroke, two different immune reactions are observed. Central responses mediated 
through the activation of resident microglial cells, and peripheral responses due to an infiltration 
of blood-derived leukocytes into the brain. Both mechanisms, although to differing degrees and 
with different complex time processes, result in post-stroke neuroinflammation [21]. 
Neuroinflammatory responses in turn induce the release of reactive oxygen species and promote 
immune-derived mechanisms associated with cytotoxicity and brain damage [22]. There exist a 
battery of possible mechanisms by which estrogens may achieve neuroprotection such as 
affecting cerebral blood flow, nitric oxide formation, leukocyte adhesion, anti-oxidative 
mechanisms, glutamate excitotoxicity and the activation state of local glial cells [8]. Microglia cells 
are the resident immune cells of the CNS and react quickly to ischemia by becoming reactive and 
producing pro- and anti-inflammatory cytokines and chemokines that initiate and perpetuate 




microglia as well as monocytes-derived macrophages (MDMs) under inflammatory conditions 
have been previously described [23-25]. By binding to nuclear estrogen receptors, microglia and 
MDMs are shifted from their activated pro-inflammatory state to an anti-inflammatory cell type [24, 
26, 27]. 
In this study, we aimed at identifying changes in the proportion/population of microglia and MDMs 
using the tMCAO male rat model after 72 h of reperfusion and concomitant estradiol substitution. 
For that, we developed an ex vivo flow cytometry technique that allows to extract living tissue from 
the infarcted cerebral cortex and subdivide the population of microglia and MDMs along their 
immunological surface pattern. Finally, quantitative studies should provide further information 
about the effectiveness of estradiol to reduce the pro-inflammatory phenotype of microglia and 
MDMs. Furthermore, microglia and MDM activation markers were investigated by a multiplex 
immunoassay at the protein level and for mRNA expression levels using RT-qPCR.  
 
Materials and Methods 
Animals and surgery  
All experimental procedures and animal care were approved by the review board for the care of 
animal subjects of the district government (LANUV, Germany, AZ: 84-02.04.2013.A212) and are 
reported in accordance with the ARRIVE guidelines. Male Wistar rats (12-14 weeks old, male, 
260-300 g, Janvier) were maintained in a pathogen-free environment with access to water and 
food ad libitum in a 12 h light/dark cycle and at controlled temperature and humidity (23±2°C; 55 
± 10 % humidity). All operations were performed between 8 and 11 a.m. Prior to surgery, rats were 
randomly assigned to receive sham or tMCAO procedure as well as 17-estradiol or vehicle 
treatment. In order to prevent dehydration, animals were subcutaneously injected with 300 μL of 
0.9 % NaCl (08779253, B. Braun); as an additional pain therapy, 0.01 mg/kg buprenorphine 
(Temgesic®, Indivior Europe Ltd.) was subcutaneously applied. Transient focal cerebral ischemia 
was induced via intraluminal occlusion of the left middle cerebral artery (MCA) for one hour as 
previously described [28]. Briefly, rats were anesthetized with 2 % isoflurane (PZN-9714675, 
Abbott) and a laser Doppler system (Moor Instruments VMS-LDF2) was used to monitor regional 
cerebral blood flow (rCBF) on both sides during surgery. After exposure of the left common carotid 
artery (CCA), internal carotid artery (ICA) and external carotid artery (ECA), the vagal nerve was 
carefully dissected from the ICA. Through the distal CCA a 0.1 % poly-L-lysine coated 3-0 
monofilament MCAO suture (404156PK5Re, Doccol) of 5 cm length was introduced into the ICA 
and advanced until an immediate drop in baseline rCBF occurred. During the entire surgical 




Tools). One hour after the occlusion, brain reperfusion was restored by removal of the filament 
and the neck incision was closed aseptically. Sham operated animals served as a control and 
were subjected to a similar surgical procedure under anesthesia (neck incision and separation of 
the bifurcation) but without occlusion of the MCA. After the surgery, animals were returned to their 
heated cages individually. As a follow-up pain management, buprenorphine was applied every 8-
12 h subcutaneously. The animals were monitored daily after surgery and finalized by transcardial 
perfusion as published previously [29]. 17-estradiol (E1024, Sigma Aldrich) was dissolved in 
ethanol (9065.4, Carl Roth) and injected subcutaneously as neck depots (500 µL, 25 µg/kg body 
weight) immediately after withdrawal of the catheter and each 12 h later for 6 times in total. Ethanol 
served as vehicle and was injected likewise. For gene expression analysis, brain samples were 
obtained from ischemic animals at 1, 3, 6, 12, 24 and 72 h post-reperfusion, for protein analysis 
at 24 and 72 h post-reperfusion and for immunohistochemistry, TTC staining and flow cytometry 
at 72 h post-reperfusion. 
 
Behavioural testing 
To investigate the effect of hormone substitutions on neurological behaviour after stroke, rats 
underwent a Garcia test scoring with some minor modifications as follows [30, 31]: 
1. Spontaneous activity was analysed for 3 min by placing the rats in the middle of the cage 
(scores: 3 = moving around, exploring the environment, and approaching at least three walls 
of the cage; 2 = slightly affected, moving around in the cage but not approaching the walls, 
nonetheless eventually rising to at least one upper rim of the cage; 1 = severely affected, not 
rising up at all and barely moving in the cage; 0 = not moving). 
2. Forepaw outstretching: rats were fixed at the tail, and the symmetry of the outstretching of 
both forelimbs was figured out (scores: 3 = both forelimbs outstretched symmetrically; 2 = right 
side moves and outstretches less than left side; 1 = right side moves slightly; 0 = right forelimb 
not moving). 
3. To assess the climbing ability, rats were placed on the wall of a wire cage (scores: 3 = climbing 
easily and gripping the wire tightly; 2 = right side impaired when climbing or not gripping as 
tightly as the left side; 1 = failing to climb or tending to circle instead of climbing). 
4. To check the body proprioception, rats were touched with a blunt stick on each side of the 
body, and the reaction to the stimulus was evaluated (scores: 3 = reacts by turning head and 
being equally startled by the stimulus on both sides; 2 = reacts slowly to stimulus on right side; 




5. Spontaneous walking activity (scores: 3 = walking straight ahead; 2 = right circling; 1 = tending 
to walk toward the right side; 0 = not moving). 
6. Sensory function was tested by brushing the vibrissae (scores: 3 = turns head to the stimulus 
side; 2 = reacts slowly to stimulus on right side; 1 = no response to stimulus on right side). 
 
TTC staining and real-time quantitative PCR 
After ischemia, rats were transcardially perfused with 0.9 % NaCl to remove blood from the brain 
vasculature. Brains were rapidly removed and cut into 2 mm coronal sections. Coronal sections 
were incubated with 2 % 2,3,5-triphenyltetrazolium chloride (TTC, T8877, Sigma) diluted in 0.9 % 
NaCl for 5 min at 37 °C. Coronal slices were arranged in a frontal to occipital order, and digital 
photographs of all stained slices were taken using a digital camera. Infarct areas were evaluated 
in a blinded manner using the open access morphometric software ImageJ 1.41. Total infarct 
volumes were calculated by adding the mean-area of each section and multiplied by 2 mm 
(thickness of the sections). Oedema correction of the infarct volume was performed using following 
paradigm: volume correction (infarct volume x contralateral volume/ipsilateral volume). Infarct size 
was quantified from images by assessing damaged tissue area in the left hemisphere via ImageJ 
software and then normalized to the total area of contralateral hemisphere.  
Gene expression and protein analysis were performed with tissues corresponding to the peri-
infarct area with 5 animals per group. The peri-infarct area can easily be observed based on the 
intensity of brick-red colour after TTC-staining. The infarct tissue appears bright white, the living 
tissue in light red and the peri-infarct in mild white as well as in colour transitions. After definition 
of the peri-infarct area, the biopsy was performed using a disposal biopsy punch, 4.0 mm from the 
frontal-parietal cortex (Bregma 1 to 3.60) and a stereomicroscope.  
Total RNA was extracted using peqGold RNA TriFast (30-2020, Peqlab) as previously described 
[32]. RNA concentration and purity were measured with the NanoDrop 1000 device (Peqlab). 
cDNA synthesis was performed using Moloney murine leukemia virus reverse transcriptase (M-
MLV) reserve transcription kit (28025-021, Thermo Fisher Scientific Inc.) and random 
hexanucleotide primers (48190-011, Invitrogen) adjusting the concentration to 1 µg/mL of total 
RNA. RT-qPCR analysis was performed using the MyIQ detection system (Biorad). Relative 
quantification was calculated by the ΔΔCt-method using the qbase+ software (Biogazelle). Data 
were expressed as relative amount of the target gene to the amount of the reference gene 
Cyclophilin A. The values of sham animals were set to 100 %. Data of interest are given as relative 







After transcardial perfusion with 0.9 % NaCl, the dissected peri-infarct areas were lysed with 
ProcartaPlex cell lysis buffer (EPX-99999-000, Invitrogen) and homogenized with microbeads for 
1 min. After centrifugation at 16,000 G for 10 min, total protein concentration of the supernatant 
was measured by BCA assay. Cytokine and chemokine 22-ProcartaPlex immunoassay (IL-1, IL-
1, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-13, IL-17A, G-CSF, GM-CSF, IFN, TNF, CXCL1, 
CXCL2, CXCL10, CCL2, CCL3, CCL5, CCL7 and CCL11) was performed according to 
manufacturer’s recommendations with provided assay solutions (EPX220-30122-901, Thermo 
Fisher Scientific Inc.). Brief, magnetic beads were transferred into each well. After a washing step 
with a hand-held magnetic plate washer and wash buffer, universal assay buffer was added to 
each well and standards as well as samples (2.5 µg/µL of total protein) were added to the 
appropriate wells. After an overnight-incubation and washing steps, the detection antibody and 
streptavidin-PE were incubated for 30 min one after another with in-between washing steps. The 
samples were measured in reading buffer with Luminex Magpix Systems and Luminex xPonent 
Software (Merck Millipore).  
 
Immunohistochemical staining 
Brains of 5 animals per group were removed after transcardial perfusion, embedded in paraffin 
and cut into 5 µm thick slides. After rehydration, antigens were unmasked by heating for 10 min 
in Tris/EDTA buffer (pH 9.0). Unspecific binding was saturated with normal serum in PBS (S-1000, 
Vector Labs), and anti-rat IBA-1 (ab107159, Abcam, 1:2,500) was incubated overnight at 4 °C to 
detect microglia and MDMs. The next day, endogenous peroxidases were blocked with H2O2, and 
a biotinylated secondary antibody rabbit-anti-goat IgG (ab6740-1, Abcam, 1:50) was incubated. A 
peroxidase-coupled avidin-biotin complex (PK-6100, Vector Laboratories) and the substrate 
diaminobenzidine (K3468, DAKO) were incubated one after another before staining the cell nuclei 
with haematoxylin (517-28-2, Merck Millipore). After dehydration, slides were mounted in DePeX 
(18243, Serva). Images were acquired with a Leica DMI 6000 B microscope and LAS X software. 
Quantification of Iba-1 positive cell counts was performed by manually counting the number of 
positive signals in the peri-infarct area of the brain. For each animal, a total of eight slices were 
analyzed with a distance of 150 μm in between. Counting was performed using a Nikon Eclipse 
55i (Nikon) and a 20x objective. Cell numbers are expressed as cells per mm2. To determine the 







After transcardial perfusion with 0.9 % NaCl, brains of at least 6 animals per group were removed, 
and both hemispheres without brainstem or cerebellum mechanically disrupted in a HBSS-based 
buffer solution (24020, Thermo Fisher Scientific Inc.). Homogenized ipsilateral and contralateral 
hemispheres were filtered separately through a 70 μm cell strainer to obtain a single cell 
suspension. After centrifugation at 220 rcf, the cell suspension was re-suspended in a 22 % percoll 
(P1644, Sigma Aldrich) gradient buffer and overlaid with ice cold DPBS (14190, Thermo Fisher 
Scientific Inc.). The gradient was conducted at 950 rcf with a reduced acceleration and no brakes. 
Unspecific binding was saturated with CD32 antibody (1:200) before the staining procedure. 
FVD560 staining served for the exclusion of dead cells, see table 2 for full antibody descriptions. 
The stained single cell suspension was measured with a BD FACS Fortessa and analyzed by the 
forward scatter (FSC), forward scatter width (FSC-W), sideward scatter (SSC), marker expression 
and mean fluorescence intensity (MFI) with the FlowJo v10 software. The gating and analysis 
were performed by two independent researchers. 
 
Statistical analysis 
JMP10 and GraphPad Prism 5 software were used for statistical analysis. Data are presented as 
arithmetic means ± SEM. Bartlett test was performed to test for equal variances. Data were 
transformed via Boxcox for homoscedasticity and indicated if applicable. Normal distribution was 
tested with Shapiro-Wilk test. One-way ANOVA followed by Tukey’s post hoc test for multiple 
comparisons or Student’s t-test were used for parametric data. Non-parametric data were 
analyzed with Kruskal-Wallis test followed by the Dunn’s multiple comparison or Mann-Whitney 
test. p < 0.05 was considered statistically significant and the following symbols were used to 
indicate the level of significance: *p < 0.05, **p < 0.005, ***p < 0.001. “ns” indicates not significant. 
Results 
Estradiol reduces the infarct volume after tMCAO 
To assess the post-ischemic neurological deficits, Garcia tests with some minor modifications 
were performed [30]. Sham animals always reached an average score of 100 %, whereas tMCAO 
animals had a significant lower score with an average of 48 % of points indicating severe motor 
deficits (figure 1 A). The application of estradiol preserved the scoring rates to 82 % which shows 
a significant improvement compared to vehicle-treated tMCAO animals. In accordance, TTC 
staining revealed that estradiol substitution significantly reduced the infarct area compared to 
vehicle-treated tMCAO animals (120 mm3 vs. 227 mm3; figure 1 B and C). Immunohistochemical 
staining of IBA-1 demonstrates that the number of microglia/macrophages is increased after 




count of IBA-1+ cells remained elevated in comparison to healthy controls and the cellular 
morphology also reflected at least in part the macrophages visible in the tMCAO group. These 
findings confirm previous data about the protective function of estradiol with respect to Garcia 
scoring, infarct volume and microgliosis [10, 11, 31, 33]. 
 
Estradiol reduces CD45+ and CD45+CD11b+CD11c+ cell numbers  
Since it has been reported that estradiol has strong anti-inflammatory effects, the number of 
resident as well as infiltrated immune cells in the ischemic hemisphere were investigated by flow 
cytometry analysis. CD45 is a marker for all leukocytes as well as microglia, CD11b and CD11c 
are markers for microglia and MDMs, and CD40 is a marker for activated microglia and MDMs. In 
a first step, we found a significant increase of CD45+ cells from 5 % to 49 % after 72 h of tMCAO 
(figure 2 A, B). This massive increase of CD45+ cells also becomes apparent in representative 
gating plots in figure 2 B. After estradiol substitution, CD45+ proportions decreased significantly to 
18 % but did not completely lapse to basal sham levels.  
To determine the concentration of microglia and MDM populations, CD11b+CD11c+ cells and 
CD11b+CD40+ cells were gated. The analysis revealed that tMCAO resulted in a significant 
expansion of the total number of CD11b+CD11c+ (from 3.5 % to 11.5 %) and of CD11b+CD40+ 
cells (from 6 % to 22 %) at 72 h tMCAO compared to sham-operated animals (figures 2 C, E). The 
CD11b+CD11c+ cell proportion was significantly reduced to 4.5 % after estradiol substitution of 
tMCAO animals and the CD11b+CD40+ gating showed a strong trend towards a lower proportion 
of those cells in estradiol-treated animals compared to vehicle-treated animals. The different 
expression patterns of CD11b, CD11c and CD40 in vehicle- and estradiol-treated animals can 
also be observed in the representative plots in figure 2 D, F. 
In the next step, we quantified the surface expression levels of CD40 by mean intensity 
fluorescence measurement following surface staining and flow cytometry analysis. CD40 is a 
surface activation marker associated with immunogenic activation of dendritic cells but also found 
in subsets of macrophages during the course of inflammation. CD40-MFI of CD45+CD11b+CD11c+ 
cells was strongly increased after tMCAO, which showed a trend towards a decrease again when 
substituting with estradiol (figure 3 A). 
 
Gene expression of microglia/monocyte markers  
To confirm our flow cytometry data, gene expression levels of selected markers were analyzed 
using RT-qPCR at different time points after tMCAO and in sham animals. After 6 h of reperfusion, 
gene expression of CD45, CD11b and CD40 were significantly induced (figure 3 B - D). 




Estradiol substitution significantly decreased the gene expression after 72 h of reperfusion of all 
four markers. 
 
Protein concentrations of inflammatory markers  
To evaluate the inflammatory profile of the ischemic brain tissue with and without estradiol 
substitution, we also measured brain levels of 22 classical inflammatory cytokines involved in post-
ischemic brain injury using a 22-plex assay. Among these pro-inflammatory chemokines, IFN, 
CXCL10, CCL2 and CCL7 showed a significantly increased protein concentration in the tMCAO 
group compared to sham operated animals (figure 4 A - D). Estradiol substitution caused a strong, 
decrease of the protein concentrations of those markers. 
 
Discussion 
Ischemic stroke accounts for approximately 80 % of all strokes, yet there are very few therapeutic 
approaches available to cure this disease. Those that exist, such as thrombolytic tissue 
plasminogen activator, are limited by a narrow therapeutic window [34]. Ischemic stroke usually 
results from a thrombotic or embolic occlusion of a major cerebral artery, most often an occlusion 
of the MCA. Therefore, related animal models such as the tMCAO rat or mouse model readily 
mimic M1 occlusion in stroke patients and so far have been of great use understanding the 
pathophysiological process of ischemic brain injury and subsequent inflammation [35].  
The chronological chain of events following brain ischemia comprises early neuronal death (within 
minutes) in the core infarct area, followed by a spreading of the infarct zone over a time course of 
the next hours, ongoing cell death in this particular region, and finally an edema formation which 
also strongly contributes to tissue damage [36-38]. Although there might exist distinct differences 
between human ischemic pathological sequela and those in rodent models, microglia and MDM 
activation typically begins as early as 2 h following the infarct onset and persists for one week or 
even longer [39]. Matching very well earlier findings, we have observed a pronounced microgliosis 
and MDM activation in the peri-infarct area at 72 h post-stroke in this study which is paralleled by 
a strong astrogliosis in our animal model [10, 11, 31, 33]. Immediately after ischemic stroke, 
activated microglia and MDMs release a set of pro-inflammatory cytokines, such as IL-1, IL-6, 
TNF- and iNOS which all contribute to driving forward neuroinflammatory responses and finally 
to neuronal apoptosis [40]. Neuroinflammation caused by activated microglia and MDMs is 
considered as a critical factor of subsequent neurological functional deficits after stroke. The 
precise mechanisms of their activation following ischemia are not completely understood. It is also 




inflammatory phenotype and promote brain recovery by clearing cell debris and releasing anti-
inflammatory cytokines and trophic factors. Thus, the balance between these opposite cell 
activities appears critical in managing tissue and cell survival. According to these pivotal roles and 
their plasticity under pathophysiological conditions, microglia and MDMs are classified into 
“classically activated” M1 phenotype and the “alternatively activated” M2 phenotypes. Generally, 
the M1 phenotype possesses more cytotoxic functions by releasing pro-inflammatory factors 
which exacerbate brain infarction and damage [41]. In contrast, the M2 phenotype produces 
numerous protective and trophic factors such as TGF-. The modulation of the balance between 
the pro- and anti-inflammatory phenotypes represents a novel and promising strategy for stroke 
treatment. 
Estradiol has been demonstrated in the past to exert a neuroprotective and anti-inflammatory role 
in the CNS after acute pathological challenges including ischemic stroke [10, 11, 24, 31, 33, 42], 
spinal cord injury [16, 43], and traumatic brain injury [13, 44]. Interestingly, sex steroids are 
assumed to contribute or even account for well-described gender differences in the above listed 
acute brain injuries [45-48]. In previous animal studies and from the literature, it appears that, 
despite sex differences in general aspects of ischemic spreading and vulnerability, the protective 
effect of 17ß-estradiol is not limited to male or female were obvious gender difference in the 
responsiveness to estradiol observed [31]. We therefore assume, although not explicitly studied 
herein, that the observed effects of 17ß-estradiol on immune cell polarization does not reflect any 
gender specificity. 
The polarization status of microglia and MDMs infiltrating the brain following ischemic injury is 
regulated and influenced by several factors and signaling mechanisms, among them also 
estrogens [18, 24, 49, 50]. We have shown here in this study and in the past that estradiol 
significantly reduces the infarct volume and improves behavioral scoring [31]. One of our 
hypotheses was that estradiol reduces microglia and MDM numbers as well as activation status. 
Indeed, we observed a highly significant reduction in the numbers of leukocytes and in particular 
of activated microglia and MDMs after estradiol treatment in the ischemic cerebral cortex using a 
standardized novel ex vivo flow cytometry approach. For that, we had to optimize the experimental 
setting to remove myelin and debris. The methodological setting leads to the consequence that 
obtained cell numbers do not reflect absolute numbers but rather relative changes due to the 
treatment. Precisely, flow cytometry analysis revealed that estradiol attenuated the percentage of 
CD45+ cell numbers which at first glance indicate a reduction of local and infiltrated immune cells 
into the ischemic hemisphere. Using a setting with triple positive cells for CD45, CD11b and 




microglia and MDMs. Following tissue injury, CD11b and CD11c are markers associated with 
infiltrating myeloid cells (monocyte-derived macrophages dendritic cells) as well as resident 
microglia, giving a mixed phenotype of various cells associated with the inflammation process. 
Accumulation of CD11c+ has been shown in several studies, arguing for a more mature, 
scavenging macrophage phenotype that is potentially also involved in the removal of cellular 
debris and therefore also in tissue regeneration in the course of brain injury regression [51-53]. 
Additional CD40 analysis showed that the reduced cell fraction mainly represents inflammatory 
activated microglia and MDMs. CD40 has been described mainly in the context of APC - T cell 
cross talk performed by dendritic cells and activated macrophages [54-57] and can be seen as a 
marker for robust, sustainable, inflammatory activation of the macrophage/dendritic cell 
population, the latter having also been described during the inflammatory phase of stroke 
associated leukocyte infiltration [58]. Time-course of gene expression in the peri-infarct zone of 
those markers used in the flow cytometry supports the above data and indicates that estradiol 
either prevents or mitigates the tMCAO-induced induction of marker genes, i.e. due to reduced 
microglia and MDM cell numbers, to cell-type specific expression levels or to a shift towards a M2 
phenotype.  
The biological effects of estradiol are mainly generated by binding and activation to its nERs. 
Besides classical nER being expressed in microglia [17, 59-61], GPR30, a seven transmembrane 
G protein-coupled receptor, is a mER which is highly expressed by microglia and significantly 
increased after ischemia [62]. This also applies to MDMs which contain a set of classical and non-
classical ERs and appear to be modulated by estradiol in their immune functions [63, 64]. GPR30 
signals through the MAP kinase pathway or by adenylyl cyclase activation [65, 66]. It has been 
shown that the activation of GPR30 significantly improved the neurological deficits and alleviated 
neuronal injuries after stroke [62]. 
There exists comprehensive information about the neuroprotective role of estradiol in the brain 
dating back to the mid-nineties of the last century [67]. In the early years of this millennium, the 
anti-inflammatory actions of estradiol in the brain was first described [68] and around the same 
time, it was suggested that neuroprotective estradiol effects are to a large extent based on the 
interaction with local microglia or invaded MDMs [69]. It is now evident that estradiol can activate 
GPR30, and this activation significantly may reduce TLR4 expression levels and NF-B activity 
and finally influence microglial and MDM activation [62]. This might be one mechanism by which 
estradiol could shift microglia and MDMs from a M1 to M2 phenotype. In previous studies, we also 
demonstrated that estradiol suppresses the NLRP3 inflammasome activation and its associated 




NLRP3-mediated signaling plays a pivotal role for cell damage during ischemic stroke [70]. Based 
on these findings it is possible that a decrease of NLPR3 inflammasome activation and its 
downstream cytokine IL-1β may be involved in facilitating the phenotype switch from M1 to M2 
after estradiol treatment during ischemia [24, 71]. Clearly, inflammation is a multi-molecule 
cascade and hence, the possibility of the involvement of several pathways and different molecular 
switches is likely and requires further studies. We and others have recently observed that estradiol 
can regulate brain neuroprotective or pro-inflammatory microRNAs in general [72] and selectively 
in microglia [42]. microRNAs act as translational repressors which destabilize or degrade RNA 
transcripts and represent thus important regulatory elements in both tissue function and disease 
[73]. To give only one relevant example, estradiol induces MIR-375 expression which is implicated 
in the suppression of BCL2 and neuroinflammation in the brain [73]. In this context, our approach 
to isolate and analyze local microglia and MDMs in the peri-infarct brain by flow cytometry should 
be extended in the future by including single cell gene expression analysis. This would allow to 
associate the phenotype switches directly to the genomic activation and deactivation of genes and 
the expression of ERs. 
In summary, our study shows that the early and continuing substitution of estradiol in male rats 
significantly dampens the activation of microglia and MDMs in the damaged cerebral cortex after 
tMCAO. This finding is supported by classical molecular and biochemical studies using selective 
gene markers for microglia and MDM activation which were reduced in their expression patterns. 
In addition, we applied a sophisticated novel approach using flow cytometry analysis with ex vivo 
tissue extracts which revealed concordant information with the molecular analyses. The latter 
method also delivers more accurate data about the subtype expression of leukocyte cell surface 
markers and will enable to picture a better chronological profile of changes of resident microglia 
and immigrated immune cells such as MDMs, T cells and B cells within the infarcted brain region 
in future. Since this study was performed on male rats only, it is difficult to speculate whether such  
regulatory protective effects by estradiol can also be seen in females. At least, an earlier study 
has shown that estradiol substitution in the tMCAO model is protective, anti-inflammatory and 
prevents microgliosis [31]. This makes it more likely that our observations may also apply to female 
rats. In favor for such an assumption are previously published data from our group concerning 
estradiol-dependent modulation of blood immune cell phenotypes and their activation status in 
adult human females [64]. This study describes a solid shift of macrophages and T cell 
subpopulations to a more protective phenotype. 
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Abbreviations 
BCL2  B-cell lymphoma 2 
CCA  Common carotid artery 
CCL  CC-chemokine ligand 
CCR  Chemokine receptor 
CD  Cluster of designation 
CNS  Central nervous system 
CycloA Cyclophilin A 
CXCL  Chemokine (C-X-C motif) ligand 
DPBS  Dulbecco's Phosphate-Buffered Saline 
E/ estradiol 17ß-estradiol 
ECA  External carotid artery 
FSC  Forward scatter 
FSC-W Forward scatter width 
GPR30 G protein-coupled receptor 30 (mER) 
HBSS  Hank's Balanced Salt Solution 
IBA-1  Ionized calcium-binding adapter molecule 1 
ICA  Internal carotid artery 
IFN  Interferon gamma 
MDM(s) Monocyte derived macrophage(s) 
mER  Membrane-bound estrogen receptor 
MFI  Mean fluorescence intensity 
MHC  Major histocompatibility complex 
M-MLV Murine leukemia virus reverse transcriptase 
nER  Nuclear estrogen receptor(s) 
NLPR  NOD-, LRR- and pyrin domain-containing protein 
rCBF  Regional cerebral blood flow 
rcf  Relative centrifugal force 
SOD  Superoxide dismutase 




tMCAO Transient middle cerebral artery occlusion 
TTC  2,3,5-triphenyltetrazolium chloride 











s      CCGTTGTACACCAGAGATGA 
as    TCCCAAAATCAGTCTGCAC 
161 bp 62 °C 
CD11b 
s      ACAGAGACCAAAGTGGAGCC 
as    GCCACCGGCTTCATTCATCA 
162 bp 60 °C 
CD40 
s      AGGTGGTCAAGAAACCAAAGGA 
as    CTGGAAGCAGCAGTGTTGTGA 
105 bp 60 °C 
CycloA 
s      GGCAAATGCTGGACCAAACAC 
as    TTAGAGTTGTCCACAGTCGGAGATG 
196 bp 65 °C 
 
Table 2 Staining panel and antibody information. 
 
  
Conjugated antibodies Manufacturer Order number 
CD32 BD Biosciences 550271 
CD45 (APC-Cy7) Biolegend 202216 
CD86 (PE) BD Biosciences 551396 
CD11b (APC) BD Biosciences 562102 
CD11c (FITC) Biorbyt ORB223665-50 
CD163 (PerCP) AB online ABIN4259472 
CD40 (eFluor450) eBioscience 48-0402-82 






CCR2 (AlexaFluor700) R&D Systems FAB8368N 






Evaluation of motor deficits, infarct volume and microglia/macrophage numbers after tMCAO 
followed by 72 h reperfusion and vehicle (veh) or estradiol (“E”) substitution compared to sham 
animals. (A) Garcia test scores (one-way ANOVA and Tukey’s post hoc test), (B) cortical infarct 
volume (Student’s t test), (C) Determination of the peri-infarct area (blue dotted circle) and 
representative pictures of TTC staining of brain slices, (D) Quantitative evaluation of the IBA-1 
staining (one-way ANOVA and Tukey’s post hoc test) and (E) representative pictures of IBA-1 
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Identification of the CD45+, CD45+CD11b+CD11c+ and CD45+CD11b+CD40+ cell populations by 
means of flow cytometry after tMCAO followed by 72 h reperfusion and estradiol substitution. (A), 
(C), (E) Evaluation of living CD45+, CD45+CD11b+CD11c+ and CD45+CD11b+CD40+ cell 
percentages (one-way ANOVA and Tukey’s post hoc test, Boxcox transformed). (B), (D), (F) 
Representative dot plots of CD45 versus FSC, CD11b versus CD11c and CD11b versus CD40 of 
sham and vehicle- or estradiol-treated tMCAO animals with the gate of interest (red box). *p < 
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MFI of the activation marker CD40 and gene expression analysis of flow cytometry markers after 
tMCAO followed by 72 h reperfusion and estradiol substitution. (A) MFI of CD40 of the 
CD45+CD11b+CD11c+ cell population (Kruskal-Wallis test and Dunn’s multiple comparison test). 
(B) Relative mRNA of the peri-infarct brain tissue of CD45 (C) CD11b and (D) CD40 of sham (red 
dotted line), vehicle-treated tMCAO animals after 1, 3, 6, 12, 24 and 72 h of reperfusion and 
estradiol-treated tMCAO animals after 72 h of reperfusion (statistical analysis was performed with 
Student’s t test or Mann-Whitney test, in part Boxcox transformed, with analysis of tMCAO + veh 



































































































































































































Protein concentrations of classical pro-inflammatory markers of peri-infarct area which were 
performed using multiplex analysis. (A) IFN (one-way ANOVA and Tukey’s post hoc test, Boxcox 
transformed), (B) CXCL10 (Kruskal-Wallis test and Dunn’s multiple comparison test), (C) CCL2 
(Kruskal-Wallis test and Dunn’s multiple comparison test) and (D) CCL7 (Kruskal-Wallis test and 
Dunn’s multiple comparison test) protein concentrations of sham, vehicle-treated animals after 24 
and 72 h of reperfusion and estradiol-treated animals after 72 h of reperfusion. *p < 0.05, **p < 




























































































































































































(A) Experimental setup and time scale of the tMCAO model and estradiol injections. (B) Gating 
strategy analyzing the height, granularity, width and living status of the cells with FlowJo v10. 
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